Pioglitazone

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (14:10, 9 January 2024) (edit) (undo)
 
(3 intermediate revisions not shown.)
Line 1: Line 1:
-
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Pioglitazone/Pioglitazone/1" align="right" caption="Pioglitazone, also known as Actos"/>
+
<StructureSection load='' size='340' side='right' caption='Pioglitazone, also known as Actos' scene='Pioglitazone/Pioglitazone/1'>
===Better Known as: Actos===
===Better Known as: Actos===
* Marketed By: Takeda Pharmaceuticals<br />
* Marketed By: Takeda Pharmaceuticals<br />
Line 11: Line 11:
===Mechanism of Action===
===Mechanism of Action===
Pioglitazone is a selective agonist for Peroxisome Proliferator-Activated Receptor Gamma ([[PPAR]]). When PPAR is not bound by ligand, it forms a complex with various co-repressors which possess histone deacetylation activity, maintaining tight chromatin structure and preventing gene transcription. This complex is released upon ligand binding (typical ligands are lipids), allowing various co-activators and co-activator-associated proteins to be recruited. Pioglitazone functions by by binding to the active site of PPARγ, causing the release of co-repressors and activation of the receptor. Activation of PPAR results in transcription of [[Molecular Playground/Insulin|insulin]] responsive genes involved in the control of glucose production, transport and utilization. This explains why the glitazones are referred to as "insulin sensitizers." <ref>PMID:9744270</ref>
Pioglitazone is a selective agonist for Peroxisome Proliferator-Activated Receptor Gamma ([[PPAR]]). When PPAR is not bound by ligand, it forms a complex with various co-repressors which possess histone deacetylation activity, maintaining tight chromatin structure and preventing gene transcription. This complex is released upon ligand binding (typical ligands are lipids), allowing various co-activators and co-activator-associated proteins to be recruited. Pioglitazone functions by by binding to the active site of PPARγ, causing the release of co-repressors and activation of the receptor. Activation of PPAR results in transcription of [[Molecular Playground/Insulin|insulin]] responsive genes involved in the control of glucose production, transport and utilization. This explains why the glitazones are referred to as "insulin sensitizers." <ref>PMID:9744270</ref>
 +
</StructureSection>
===Pharmacokinetics===
===Pharmacokinetics===
-
 
+
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">
-
{| class="wikitable" border="1" width="40%" style="text-align:center"
+
<tr>
-
|-
+
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
-
! colspan="6" align="center"| Glitazone [[Pharmacokinetics]] Comparison at Equivalent Dosages <ref>doi: 10.1111/j.1365-2125.2007.02986.x</ref><ref>PMID:18997160</ref><ref>PMID: 9454824</ref><ref>PMID: 17594391</ref>
+
<div style="height:100%; width: 100%">
-
|-
+
{{:Glitazone Pharmacokinetics}}
-
! Parameter
+
</div>
-
! [[Pioglitazone]] (Actos)
+
</td>
-
! [[Rosiglitazone]] (Avandia)
+
</tr>
-
 
+
</table>
-
|-
+
-
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
+
-
! 1.8
+
-
! 1
+
-
 
+
-
|-
+
-
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
+
-
! 617
+
-
! 361
+
-
|-
+
-
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
+
-
! 83
+
-
! 99
+
-
|-
+
-
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
+
-
! 99
+
-
! 99
+
-
|-
+
-
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+
-
! 3-8
+
-
! 3-4
+
-
|-
+
-
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+
-
! 6244
+
-
! 2024
+
-
|-
+
-
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+
-
! 360
+
-
! 10
+
-
|-
+
-
! Equivalent Dosage (mg)
+
-
! 30
+
-
! 4
+
-
|-
+
-
! Metabolism
+
-
! Hepatic <br/>(CYP2C8)
+
-
! Hepatic <br/>(CYP2C8)
+
-
|}
+
===References===
===References===

Current revision

Pioglitazone, also known as Actos

Drag the structure with the mouse to rotate

Pharmacokinetics

Glitazone Pharmacokinetics Comparison at Equivalent Dosages
Parameter Pioglitazone (Actos) Rosiglitazone (Avandia)
Tmax (hr) 1.8 1
Cmax (ng/ml) 617 361
Bioavailability (%) 83 99
Protein Binding (%) 99 99
T1/2 (hr) 3-8 3-4
AUC (ng/ml/hr) 6244 2024
IC50 (nM) 360 10
Equivalent Dosage (mg) 30 4
Metabolism Hepatic
(CYP2C8)
Hepatic
(CYP2C8)

For Pharmacokinetic Data References, See: References

References

  1. http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=ACTOS
  2. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998 Sep 10;395(6698):137-43. PMID:9744270 doi:10.1038/25931


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Personal tools